1 Min Read
April 4 (Reuters) - Abivax SA:
* Initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV patients
* Initial results are expected in Q3 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.